Signaling Pathways Involved in Colorectal Cancer: Pathogenesis and Targeted Therapy

Overview

Journal Signal Transduct Target Ther

Specialties Cell Biology
Pharmacology

Date 2024 Oct 6

PMID 39370455

Authors

Qing Li

Shan Geng

Hao Luo

Wei Wang

Ya-Qi Mo

Qing Luo

Lu Wang

Guan-Bin Song

Jian-Peng Sheng

Bo Xu

Affiliations

Soon will be listed here.

Abstract

Colorectal cancer (CRC) remains one of the leading causes of cancer-related mortality worldwide. Its complexity is influenced by various signal transduction networks that govern cellular proliferation, survival, differentiation, and apoptosis. The pathogenesis of CRC is a testament to the dysregulation of these signaling cascades, which culminates in the malignant transformation of colonic epithelium. This review aims to dissect the foundational signaling mechanisms implicated in CRC, to elucidate the generalized principles underpinning neoplastic evolution and progression. We discuss the molecular hallmarks of CRC, including the genomic, epigenomic and microbial features of CRC to highlight the role of signal transduction in the orchestration of the tumorigenic process. Concurrently, we review the advent of targeted and immune therapies in CRC, assessing their impact on the current clinical landscape. The development of these therapies has been informed by a deepening understanding of oncogenic signaling, leading to the identification of key nodes within these networks that can be exploited pharmacologically. Furthermore, we explore the potential of integrating AI to enhance the precision of therapeutic targeting and patient stratification, emphasizing their role in personalized medicine. In summary, our review captures the dynamic interplay between aberrant signaling in CRC pathogenesis and the concerted efforts to counteract these changes through targeted therapeutic strategies, ultimately aiming to pave the way for improved prognosis and personalized treatment modalities in colorectal cancer.

Citing Articles

The Role of Reactive Oxygen Species in Colorectal Cancer Initiation and Progression: Perspectives on Theranostic Approaches.

Catalano T, Selvaggi F, Cotellese R, Aceto G Cancers (Basel). 2025; 17(5).

PMID: 40075600 PMC: 11899472. DOI: 10.3390/cancers17050752.

Eudragit S 100 Assisted Molecular Solid Dispersion of Andrographolide Tendered Augmented Drug Delivery and Apoptosis in Human Colon Cancer, HT-29 Cells.

Devangan P, Sharma A, Wadate N, Mourya A, Madan J AAPS PharmSciTech. 2025; 26(3):82.

PMID: 40069524 DOI: 10.1208/s12249-025-03073-z.

Investigating the PI3K/AKT/mTOR axis in Buzhong Yiqi Decoction's anti-colorectal cancer activity.

Qiao S, Li X, Yang S, Hua H, Mao C, Lu W Sci Rep. 2025; 15(1):8238.

PMID: 40065054 PMC: 11893811. DOI: 10.1038/s41598-025-89018-9.

Establishment of a novel mouse model of colorectal cancer by orthotopic transplantation.

Chen C, Fu Q, Wang L, Tanaka S, Imajo M BMC Cancer. 2025; 25(1):405.

PMID: 40050746 PMC: 11884030. DOI: 10.1186/s12885-025-13834-5.

β2-Chimaerin Deficiency Favors Polyp Growth in the Colon of Apc Mice.

Velasco-Sampedro E, Sanchez-Vicente C, Caloca M Molecules. 2025; 30(4).

PMID: 40005135 PMC: 11858732. DOI: 10.3390/molecules30040824.

References

Jones S, Emmerson P, Maynard J, Best J, Jordan S, Williams G . Biallelic germline mutations in MYH predispose to multiple colorectal adenoma and somatic G:C-->T:A mutations. Hum Mol Genet. 2002; 11(23):2961-7. DOI: 10.1093/hmg/11.23.2961. View

Sahin U, Oehm P, Derhovanessian E, Jabulowsky R, Vormehr M, Gold M . An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature. 2020; 585(7823):107-112. DOI: 10.1038/s41586-020-2537-9. View

Weichert W, Roske A, Niesporek S, Noske A, Buckendahl A, Dietel M . Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clin Cancer Res. 2008; 14(6):1669-77. DOI: 10.1158/1078-0432.CCR-07-0990. View

Tsoi H, Chu E, Zhang X, Sheng J, Nakatsu G, Ng S . Peptostreptococcus anaerobius Induces Intracellular Cholesterol Biosynthesis in Colon Cells to Induce Proliferation and Causes Dysplasia in Mice. Gastroenterology. 2017; 152(6):1419-1433.e5. DOI: 10.1053/j.gastro.2017.01.009. View

Kouzarides T . Chromatin modifications and their function. Cell. 2007; 128(4):693-705. DOI: 10.1016/j.cell.2007.02.005. View

Dembic Z, Haas W, Weiss S, McCubrey J, Kiefer H, von Boehmer H . Transfer of specificity by murine alpha and beta T-cell receptor genes. Nature. 1986; 320(6059):232-8. DOI: 10.1038/320232a0. View

Shen L, Catalano P, Benson 3rd A, ODwyer P, Hamilton S, Issa J . Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil based chemotherapy. Clin Cancer Res. 2007; 13(20):6093-8. PMC: 3575642. DOI: 10.1158/1078-0432.CCR-07-1011. View

Chong W, Zhu X, Ren H, Ye C, Xu K, Wang Z . Integrated multi-omics characterization of KRAS mutant colorectal cancer. Theranostics. 2022; 12(11):5138-5154. PMC: 9274732. DOI: 10.7150/thno.73089. View

Aykut B, Pushalkar S, Chen R, Li Q, Abengozar R, Kim J . The fungal mycobiome promotes pancreatic oncogenesis via activation of MBL. Nature. 2019; 574(7777):264-267. PMC: 6858566. DOI: 10.1038/s41586-019-1608-2. View

10.

Lombardo Y, Scopelliti A, Cammareri P, Todaro M, Iovino F, Ricci-Vitiani L . Bone morphogenetic protein 4 induces differentiation of colorectal cancer stem cells and increases their response to chemotherapy in mice. Gastroenterology. 2010; 140(1):297-309. DOI: 10.1053/j.gastro.2010.10.005. View

11.

Prossomariti A, Piazzi G, DAngelo L, Miccoli S, Turchetti D, Alquati C . miR-155 Is Downregulated in Familial Adenomatous Polyposis and Modulates WNT Signaling by Targeting AXIN1 and TCF4. Mol Cancer Res. 2018; 16(12):1965-1976. DOI: 10.1158/1541-7786.MCR-18-0115. View

12.

Reddy B, Narisawa T, Wright P, Vukusich D, WEISBURGER J, Wynder E . Colon carcinogenesis with azoxymethane and dimethylhydrazine in germ-free rats. Cancer Res. 1975; 35(2):287-90. View

13.

Yonesaka K, Zejnullahu K, Okamoto I, Satoh T, Cappuzzo F, Souglakos J . Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med. 2011; 3(99):99ra86. PMC: 3268675. DOI: 10.1126/scitranslmed.3002442. View

14.

Seifert J, Mlodzik M . Frizzled/PCP signalling: a conserved mechanism regulating cell polarity and directed motility. Nat Rev Genet. 2007; 8(2):126-38. DOI: 10.1038/nrg2042. View

15.

Yamashita R, Long J, Longacre T, Peng L, Berry G, Martin B . Deep learning model for the prediction of microsatellite instability in colorectal cancer: a diagnostic study. Lancet Oncol. 2021; 22(1):132-141. DOI: 10.1016/S1470-2045(20)30535-0. View

16.

Sampson J, Dolwani S, Jones S, Eccles D, Ellis A, Evans D . Autosomal recessive colorectal adenomatous polyposis due to inherited mutations of MYH. Lancet. 2003; 362(9377):39-41. DOI: 10.1016/S0140-6736(03)13805-6. View

17.

Azad N, Zahnow C, Rudin C, Baylin S . The future of epigenetic therapy in solid tumours--lessons from the past. Nat Rev Clin Oncol. 2013; 10(5):256-66. PMC: 3730253. DOI: 10.1038/nrclinonc.2013.42. View

18.

Choi H, Chung T, Kang S, Lee Y, Ko J, Kim J . Ganglioside GM3 modulates tumor suppressor PTEN-mediated cell cycle progression--transcriptional induction of p21(WAF1) and p27(kip1) by inhibition of PI-3K/AKT pathway. Glycobiology. 2006; 16(7):573-83. DOI: 10.1093/glycob/cwj105. View

19.

Agarwal A, Balic M, El-Ashry D, Cote R . Circulating Tumor Cells: Strategies for Capture, Analyses, and Propagation. Cancer J. 2018; 24(2):70-77. PMC: 5880323. DOI: 10.1097/PPO.0000000000000310. View

20.

Schreiber R, Old L, Smyth M . Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011; 331(6024):1565-70. DOI: 10.1126/science.1203486. View